Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 14 1 2020 01 01 1 10 Hitoshi Yoshida Department of Hematology , Osaka International Cancer Institute, Osaka, Japan Midori Koike Department of Hematology , Osaka International Cancer Institute, Osaka, Japan Yuma Tada Department of Hematology , Osaka International Cancer Institute, Osaka, Japan Keiichi Nakata Department of Hematology , Osaka International Cancer Institute, Osaka, Japan Akihisa Hino Department of Hematology , Osaka International Cancer Institute, Osaka, Japan Shigeo Fuji Department of Hematology , Osaka International Cancer Institute, Osaka, Japan Hiroaki Masaie Department of Hematology , Osaka International Cancer Institute, Osaka, Japan Chihiro Oka Department of Laboratory, Osaka International Cancer Institute, Osaka, Japan Akemi Higeno Department of Laboratory, Osaka International Cancer Institute, Osaka, Japan Atushi Idota Department of Laboratory, Osaka International Cancer Institute, Osaka, Japan Tomoyuki Yamasaki Department of Laboratory, Osaka International Cancer Institute, Osaka, Japan Jun Ishikawa Department of Hematology , Osaka International Cancer Institute, Osaka, Japan 2019 04 09 2019 12 07 Background: Advances of allogeneic hematopoietic cell transplantation (allo-HCT) have brought long-term survival to the patients with hematologic malignancies.  Chronic graft-versus-host disease (GVHD) is one of major problems for the long-survivors after allo-HCT.  Dysregulation of immune reconstitution has been reported to be involved in the pathogenesis of chronic GVHD.  Differences of immune reconstitution between cord blood transplantation (CBT) and unrelated bone marrow transplantation (uBMT) remain unclear in long-term survivors.  We investigated immune reconstitution in patients who survive for more than 2 years after CBT (n=21) or uBMT (n=20) without relapse of underlying disease. Materials and Methods: Using flowcytomeric analysis of peripheral blood, we investigated immune reconstitution of T cells, B cells, and NK cells between CBT and uBMT patients.  We collected clinical data regarding allo-HCT and examined the relation of immune reconstitution to the development of chronic GVHD. Results: Between CBT and uBMT patients, we found significant differences in absolute cell number of CD8+ as well as CD19+ cell and CD4/CD8 ratio even more than 2 years after allo-HCT.  Among uBMT patients, absolute cell number of naïve CD4+ cell was significantly lower in patients with chronic GVHD.  In addition, we found significant differences in absolute cell number of CD19+ cell, especially naïve B cell between patients with and without chronic GVHD in both CBT and uBMT patients.  Conclusion: These results suggest that differences of immune recovery between CBT and uBMT patients may exist even in patients who survive for more than 2 years and might be related to the development of chronic GVHD.  https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1107 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1107/806

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 14 1 2020 01 01 11 18 Ladan Nekoohesh Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. AND Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Mohammad Ghahremani Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. AND Department of Pharmacology-Toxicology, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Shahrbanoo Rostami Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Mohsen Nikbakht Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Leila Nekoohesh Department of Medical Biotechnology, School of Advanced Technologies in Medicine, International Campus, Tehran University of Medical Sciences, Tehran, Iran Roozbeh Naemi School of Life Sciences and Education, Staffordshire University, Science Centre, Stoke on Trent UK Saeed Mohammadi Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Laya Ghadyaninejad Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Seyed Asadollah Mousavi Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Mohammad Vaezi Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Kamran Alimoghaddam Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Bahram Chahardouli Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran. 2019 12 31 2019 12 31 Background: The present study investigated the patients with Chronic Myeloid Leukemia in chronic phase (CP-CML) who had beenon the first- line Imatinib Mesylate (IM) therapy for a period of 84 months. Materials and Methods: This retrospective study was conducted in 295 newly-diagnosed CP-CML patients(age >18 years)who were admitted to the Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran during 1 January 2009 to 30 December 2016. Response to treatment was evaluated by molecular response assessment. Rates of IM dose adjustment, switching to another drug therapy, Progression to Accelerate Phase (AP) and Blastic Crisis (BC) and long-term outcomes included Overall Survival (OS) and Progression Free Survival (PFS) were assesed. Results: Patients’ average age was 41.7 years, and 52.9% were male. 44.4% of patients at the month 18 achieved Major Molecular Response (MMR). Progression to AP/BC occurred in 26 patients during 84 months, and the estimated rate of OS and PFS were 71.83 and 74.48, respectively. Among the patients who didn’t achieve MMR at month 18 , 61 patients were treated with IM ( 400 mg /day), and then after month 18, 24(39.3%) of whom  achieved MMR. Dose adjustments occurred in 60 patients (20.33%). IM dose increases were observed in 53 patients who didn’t achive optimal response to imatinib or loss of optimal response. IM dose decreases were observed in 7 patients. 25 (8.47%)  patients were switched to a different Tyrosine Kinase Inhibitor (TKI). Most of TKI changes(n=21) happened in patients who didn’t achieve optimal response to IM and for the 4 patients TKI changes were owing to adverse events of IM. Among the patients undergoing change in treatment, 24(43.75%) patient achieved MMR. Conclusion: Our data showed the high effectiveness of the change in the treatment of IM-resistant condition. Moreover, our finding suggests that imatinib be effective in Iranian patients after a long period of time compared to the referenced studies. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1244 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1244/807

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 14 1 2020 01 01 19 26 EN Samira Abbasi Department of Psychiatric Nursing, School of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran Mohsen Shahriari Department of Adult Health Nursing, School of Nursing and Midwifery, Nursing and Midwifery Care Research Centre, Isfahan, Iran Majid Ghanavat Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran Sedigheh Talakoub Department of Pediatrics, School of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran Fatemeh Sadat Mosavi Asl NICU Ward, Gharazi Hospital, Isfahan, Iran Zeinab Hemati Department of Pediatrics, School of Nursing and Midwifery, Nursing and Midwifery Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran 2019 02 18 2019 11 02 Background:Thalassemia as a chronic disease could affect different aspects of a patient’s life. On the other hand, when encountering the symptoms of a chronic disease as a stressful factor, the coping strategy of the adolescents and their families could have an important role in the quality of life of these patients. The present study was conducted to determine the relation between different aspects of quality of life with coping styles in the adolescents with thalassemia in comparison to a healthy control group. Materials and Methods: The present study is a case-control research in 2017. Studied samples were 200 adolescents with thalassemia and healthy adolescents. Data gathering tools were demographic characteristics checklist and the coping style and quality of life questionnaire by the World Health Organization. Data were analyzed by SPSS 20 using independent t-test, linear regression and correlation coefficients. Conclusion:Results of Pearson statistical test showed a positive and significant relation between the total mean score of quality of life and its physical, social and mental aspects with emotion-oriented coping style (p<0.01). Also a direct significant relation was observed between the total mean score of quality of life and its social and physical aspects with problem-oriented coping style(p<0.01). Conclusion: According to the results of the present study, educating the adolescents and their families for paying attention to the coping style for stressful factors and preparing these adolescents for passing toward the youth period, which could be challenging for them, are highly recommended.  https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1085 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1085/816

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 14 1 2020 01 01 27 37 Wafaa El- Neanaey Department of Clinical and Chemical Pathology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt Rania Swelem Department of Clinical and Chemical Pathology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt Omar Ghallab Department of Internal Medicine (Hematology), Faculty of Medicine, University of Alexandria, Alexandria, Egypt Sara Abu-Shelou Department of Clinical and Chemical Pathology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt 2019 05 14 2019 09 02 Background: The present work aimed to investigate the expression of CD160/ CD200 in CLL and other mature B-cell neoplasms (MBN) and their use as an additional diagnostic tool for differentiating CLL from other MBN. Materials and Methods: Using flowcytometry, we detected the expression of CD160 &CD200 on B-cells from 30 CLL patients, 30 other MBN patients in addition to 20 controls. CDs160/200 measurements were determined as a percentage expression (≥20% was considered positive) and as a ratio of the mean fluorescence intensities (MFIR) of leukemic cells/controls and were considered positive when the ratios were ≥2 and 20, respectively. Results: 90% and 100% of the CLL group expressed CDs160/200 in comparison to 60% and 63.3% of other MBN (p=0.007, p<0.001) respectively. By MFIR; 96.7% and 50% of our CLL group expressed CDs160/200 in comparison to 76.7% and 30% of other MBN, respectively. CDs160/ 200 were not expressed on the controls. Positive co-expression of CD160 and CD200 was found in 90% of the CLL cases, 60% of HCL patients & only in 40% of B-NHL. However, double negative expression of both markers was found only in 24% of the B-NHL patients. Conclusion: CD160 with CD200 can be used as additional diagnostic markers to the available routine panel to differentiate between B-CLL & other non-specified B-NHL patients.   https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1131 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1131/809

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 14 1 2020 01 01 38 44 EN Hayedeh Javadzadeh Shahshahani Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran Azam Hayati Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Yazd, Iran 2019 04 15 2019 12 23 Background: Blood group testing is an important part of supplying safe blood components in blood transfusion centers. Blood group discrepancy develops when reactions in forward grouping do not correspond with reverse grouping or if the preceding and recent results do not match. This study aimed to evaluate ABO blood group discrepancies among blood donors of Yazd, Iran. Materials and Methods: In this cross-sectional study, data of blood donors were obtained from the integrated database of Yazd Blood Transfusion Center during a period of eight years (2010 – 2017). Tube testing was used for determining the ABO blood groups. A serological workup was performed for diagnosis and determination of the discrepancy. Confirmation of the results was accomplished by the reference laboratory of immunohematology. Results: Blood group discrepancies were detected in 130 (0.04%) out of 322,222 donations. Technical/Clerical errors leading to ABO discrepancy were noticed in 12 (9.3%) cases. The most frequent cause of ABO discrepancies in forward grouping was subgroups of A Antigen (44.6%) and in reverse grouping was cold autoantibody (23.9%). There were 11 (8.4%) cases with alloantibodies. Two blood donors with rare Bombay phenotype and p blood group were also identified. Conclusion: For minimizing Technical/Clerical errors, accurate blood donor or sample identification programs should be implemented. All cases of blood group discrepancies should be carefully investigated, and blood donors should be informed appropriately. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1113 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1113/810

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 14 1 2020 01 01 < Fatemeh Safari Department of Biology, Payame Noor University, Tehran, Iran Reza Haji Hosseini Haji Hosseini Department of Biology, Payame Noor University, Tehran, Iran Rick F. Thorne 1)Translational Research Institute, Henan Provincial People’s Hospital, Academy of Medical Science, Zhengzhou University, Zhengzhou 450003, China 2) School of Environmental & Life Sciences, University of Newcastle, NSW 2258, Australia Ardeshir Ghavamzadeh Cancer & Cell Therapy Research Center, Tehran University of Medical Sciences, Tehran, Iran 2021 05 24 2022 12 31 Background: FAT atypical cadherin 1 (FAT1) is a member of the cadherin superfamily whose loss or gain is associated with the initiation and/or progression of different cancers. FAT1 overexpression has been reported in hematological malignancies. This research intended to investigate FAT1 gene expression in adult Iranian acute leukemia patients, compared to normal mobilized peripheral blood CD34+ cells. Materials and Methods: The peripheral blast (peripheral blood mononuclear cells) cells of 22 acute myeloid leukemia (AML), 14 acute lymphoid leukemia (ALL) patients, and mobilized peripheral blood CD34+ cells of 12 healthy volunteer stem cell donors were collected. Then, quantitative real-time polymerase chain reaction (qPCR) was used to compare FAT1 gene expression. Results: Overall, there were no significant differences in FAT1 expression between AML and ALL patients (p>0.2). Nonetheless, the mean expression level of FAT1 was significantly higher in leukemic patients (AML and ALL) than in normal CD34+ cells (p=0.029). Additionally, the FAT1 expression levels were significantly higher in both CD34+ and CD34- leukemic patients than in normal CD34+ cells (p=0.028). Conclusion: No significant differences were found between FAT1 expression in CD34+ and CD34- leukemic samples (p> 0.3). Thus, higher FAT1 expression was evident in ALL and AML leukemia cells but this appeared unrelated to CD34 expression. This suggests in a proportion of adult acute leukemias, FAT1 expression may prove to be a suitable target for therapeutic strategies. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1643 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1643/967

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 17 2 2023 04 17 89 99 Farhad Shahi Breast Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran Reza Safaee Department of Medical Oncology, Tehran University of Medical Sciences, Tehran, Iran Saba Fekrvand Tehran University of Medical Sciences, School of Medicine, Tehran, Iran Fatemeh Fathi Tehran University of Medical Sciences, School of Medicine, Tehran, Iran Mohammad Reza Dabiri Department of Medical Oncology, Tehran University of Medical Sciences, Tehran, Iran Alireza Abdollahi Department of Pathology, School of Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran Hanieh Hosseini Department of Internal Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran 2022 07 26 2023 03 15 Background: Since 2019, Coronavirus has been a highly contagious disease. The COVID-19 outbreak was declared a pandemic by the World Health Organization in March 2020. Variable laboratory findings are reported in COVID-19 patients, among which elevated levels of D-dimer, lactate dehydrogenase, as well as lymphopenia, have been reported to be associated with increased severity of disease symptoms requiring ventilator support, intensive care unit admission, and mortality. Materials and Methods: In the current study, inclusion criteria were: patient age above 18 years and hospitalization in the Imam Khomeini hospital with COVID-19 disease confirmed with nasopharyngeal swab polymerase chain reaction tests. Levels of white blood cells, neutrophils, lymphocytes, hemoglobin, platelets, D-dimer, C-reactive protein, LDH, and ferritin were measured and their correlation with the final patients’ outcome was evaluated. Results: A total of 208 patients were included in the present study. Higher neutrophil to lymphocyte ratio, (WBC count excluding lymphocyte)/lymphocyte, LDH, platelet to lymphocyte ratio, ferritin, and D-dimer were significantly related to O2 dependency. Neutrophil to lymphocyte ratio, (WBC count excluding lymphocyte)/lymphocyte and LDH were significantly related to higher rates of mortality. Higher Hb and lymphocyte count were significantly related to higher rates of survival. Conclusion: Hematological parameters including neutrophil to lymphocyte ratio, (WBC count excluding lymphocyte)/lymphocyte, LDH, platelet to lymphocyte ratio, ferritin, D-dimer, Hb, and lymphocyte count were significantly related to the prognosis of patients with COVID-19 disease. This could help decide which COVID-19 patients have priority for hospitalization and intensive medical care, particularly when the pandemic disease causes limitations in healthcare service. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1883 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1883/968

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 17 2 2023 04 17 100 105 Ata Abbasi Department of Pathology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran Farzaneh Ghaffarizadeh Department of Pathology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran Hengameh Mojdeganlou Department of Pathology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran 2020 12 26 2022 02 06 Background: Breast cancer is the most common malignant tumor and cause of death in women. Factors that play role in tumor metastasis are lymph node involvement, lack of tumor differentiation and hormone receptor expression, high proliferation rate, and angiogenesis. In the present study, we tried to evaluate the microvessel density (MVD) using Immunohistochemistry for the CD34 marker to investigate the amount of angiogenesis in breast cancer and its relationship with other histopathological parameters and compare it with normal tissue. Materials and Methods: 58 paraffin-embedded samples of breast cancer were enrolled. All blocks were sectioned and stained for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2(HER 2/neu), ki67, and CD34 by immunohistochemistry (IHC) method. Results: The mean age of patients in this study was 49.6 ± 10.6 years. Statistically, there was a significant relationship between the grade of the tumor (P = 0.01), absence of expression of estrogen receptor (P = 0.008), and progesterone receptor (P = 0.003) with MVD. Conclusion: Due to the association between MVD, tumor grade, and absence of ER and PR expression, this valuable marker can play an important role in the prediction of prognosis in breast cancer patients and can lead to new targeted therapy in the future.  https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1507 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1507/969

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 17 2 2023 04 17 106 113 EN Mani Ramzi Hematology Research Center and Department of Bone Marrow Transplantation, Shiraz University of Medical Sciences, Shiraz, Iran Elaheh Vafaie Hematology Research Center and Department of Bone Marrow Transplantation, Shiraz University of Medical Sciences, Shiraz, Iran Hourvash Haghighinejad Medical School , Shiraz University of Medical Sciences, Shiraz, Iran Hashim Imran Medical School, Shiraz University of Medical Sciences, Shiraz, Iran 2022 11 07 2023 03 15 Background: High-dose chemotherapy followed by Autologous SCT (stem cell transplantation) is a treatment of choice for relapsed and refractory lymphoma. Due to cost, toxicity, and shortage of Carmustine, we decided to conduct a phase 2 clinical trial to evaluate the safety and efficacy of Bendamustine instead of Carmustine in a previously used BEAM-like protocol. Materials and Methods:102 pati